361 related articles for article (PubMed ID: 23515710)
1. The clinical characteristics and prognostic significance of MN1 gene and MN1-associated microRNA expression in adult patients with de novo acute myeloid leukemia.
Xiang L; Li M; Liu Y; Cen J; Chen Z; Zhen X; Xie X; Cao X; Gu W
Ann Hematol; 2013 Aug; 92(8):1063-9. PubMed ID: 23515710
[TBL] [Abstract][Full Text] [Related]
2. MN1, FOXP1 and hsa-miR-181a-5p as prognostic markers in acute myeloid leukemia patients treated with intensive induction chemotherapy and autologous stem cell transplantation.
Seipel K; Messerli C; Wiedemann G; Bacher U; Pabst T
Leuk Res; 2020 Feb; 89():106296. PubMed ID: 31927137
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic stem cell transplantation mitigates the adverse prognostic impact of high diagnostic BAALC and MN1 expression in AML.
Jentzsch M; Bill M; Grimm J; Brauer D; Backhaus D; Goldmann K; Schulz J; Niederwieser D; Platzbecker U; Schwind S
Ann Hematol; 2020 Oct; 99(10):2417-2427. PubMed ID: 32862286
[TBL] [Abstract][Full Text] [Related]
4. Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.
Langer C; Marcucci G; Holland KB; Radmacher MD; Maharry K; Paschka P; Whitman SP; Mrózek K; Baldus CD; Vij R; Powell BL; Carroll AJ; Kolitz JE; Caligiuri MA; Larson RA; Bloomfield CD
J Clin Oncol; 2009 Jul; 27(19):3198-204. PubMed ID: 19451432
[TBL] [Abstract][Full Text] [Related]
5. Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia.
Schwind S; Marcucci G; Kohlschmidt J; Radmacher MD; Mrózek K; Maharry K; Becker H; Metzeler KH; Whitman SP; Wu YZ; Powell BL; Baer MR; Kolitz JE; Carroll AJ; Larson RA; Caligiuri MA; Bloomfield CD
Blood; 2011 Oct; 118(15):4188-98. PubMed ID: 21828125
[TBL] [Abstract][Full Text] [Related]
6. Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study.
Thomas X; Suciu S; Rio B; Leone G; Broccia G; Fillet G; Jehn U; Feremans W; Meloni G; Vignetti M; de Witte T; Amadori S
Haematologica; 2007 Mar; 92(3):389-96. PubMed ID: 17339189
[TBL] [Abstract][Full Text] [Related]
7. miR-10a overexpression is associated with NPM1 mutations and MDM4 downregulation in intermediate-risk acute myeloid leukemia.
Ovcharenko D; Stölzel F; Poitz D; Fierro F; Schaich M; Neubauer A; Kelnar K; Davison T; Müller-Tidow C; Thiede C; Bornhäuser M; Ehninger G; Brown D; Illmer T
Exp Hematol; 2011 Oct; 39(10):1030-1042.e7. PubMed ID: 21784052
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the clinical relevance of the expression and function of P-glycoprotein, multidrug resistance protein and lung resistance protein in patients with primary acute myelogenous leukemia.
Tsimberidou AM; Paterakis G; Androutsos G; Anagnostopoulos N; Galanopoulos A; Kalmantis T; Meletis J; Rombos Y; Sagriotis A; Symeonidis A; Tiniakou M; Zoumbos N; Yataganas X
Leuk Res; 2002 Feb; 26(2):143-54. PubMed ID: 11755464
[TBL] [Abstract][Full Text] [Related]
9. Upregulated microRNA-146a expression induced by granulocyte colony-stimulating factor enhanced low-dosage chemotherapy response in aged acute myeloid leukemia patients.
Li X; Xu L; Sheng X; Cai J; Liu J; Yin T; Xiao F; Chen F; Zhong H
Exp Hematol; 2018 Dec; 68():66-79.e3. PubMed ID: 30208330
[TBL] [Abstract][Full Text] [Related]
10. Integrative nucleophosmin mutation-associated microRNA and gene expression pattern analysis identifies novel microRNA - target gene interactions in acute myeloid leukemia.
Russ AC; Sander S; Lück SC; Lang KM; Bauer M; Rücker FG; Kestler HA; Schlenk RF; Döhner H; Holzmann K; Döhner K; Bullinger L
Haematologica; 2011 Dec; 96(12):1783-91. PubMed ID: 21880628
[TBL] [Abstract][Full Text] [Related]
11. High-dose cytarabine, idarubicin, and granulocyte colony-stimulating factor remission induction therapy for previously untreated de novo and secondary adult acute myeloid leukemia.
Baer MR; Christiansen NP; Frankel SR; Brunetto VL; Mrózek K; Bloomfield CD; Herzig GP
Semin Oncol; 1993 Dec; 20(6 Suppl 8):6-12. PubMed ID: 7507264
[TBL] [Abstract][Full Text] [Related]
12. High bone marrow miR-19b level predicts poor prognosis and disease recurrence in de novo acute myeloid leukemia.
Zhang TJ; Lin J; Zhou JD; Li XX; Zhang W; Guo H; Xu ZJ; Yan Y; Ma JC; Qian J
Gene; 2018 Jan; 640():79-85. PubMed ID: 29032147
[TBL] [Abstract][Full Text] [Related]
13. Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry.
Guerci A; Merlin JL; Missoum N; Feldmann L; Marchal S; Witz F; Rose C; Guerci O
Blood; 1995 Apr; 85(8):2147-53. PubMed ID: 7536492
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of combined BAALC and MN1 gene expression level in acute myeloid leukemia with normal karyotype.
Marjanovic I; Karan-Djurasevic T; Kostic T; Virijevic M; Vukovic NS; Pavlovic S; Tosic N
Int J Lab Hematol; 2021 Jun; 43(3):433-440. PubMed ID: 33242229
[TBL] [Abstract][Full Text] [Related]
15. De novo acute myeloid leukemia with multilineage dysplasia: treatment results and prognostic evaluation from a series of 44 patients treated with fludarabine, cytarabine and G-CSF (FLAG).
Ferrara F; Palmieri S; Pocali B; Pollio F; Viola A; Annunziata S; Sebastio L; Schiavone EM; Mele G; Gianfaldoni G; Leoni F
Eur J Haematol; 2002 Apr; 68(4):203-9. PubMed ID: 12071935
[TBL] [Abstract][Full Text] [Related]
16. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia.
Parker JE; Pagliuca A; Mijovic A; Cullis JO; Czepulkowski B; Rassam SM; Samaratunga IR; Grace R; Gover PA; Mufti GJ
Br J Haematol; 1997 Dec; 99(4):939-44. PubMed ID: 9432047
[TBL] [Abstract][Full Text] [Related]
17. Low miR-34c expression is associated with poor outcome in de novo acute myeloid leukemia.
Yang DQ; Zhou JD; Wang YX; Deng ZQ; Yang J; Yao DM; Qian Z; Yang L; Lin J; Qian J
Int J Lab Hematol; 2017 Feb; 39(1):42-50. PubMed ID: 27577964
[TBL] [Abstract][Full Text] [Related]
18. Anthracycline drugs and MDR expression in human leukemia.
Pogliani EM; Belotti D; Rivolta GF; Maffè PF; Corneo G
Cytotechnology; 1996; 19(3):229-35. PubMed ID: 8862011
[TBL] [Abstract][Full Text] [Related]
19. The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia.
Scholl C; Schlenk RF; Eiwen K; Döhner H; Fröhling S; Döhner K;
Haematologica; 2005 Dec; 90(12):1626-34. PubMed ID: 16330435
[TBL] [Abstract][Full Text] [Related]
20. Impact of the expression of P glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53, and heat shock protein 27 on response to induction therapy and long-term survival in patients with de novo acute myeloid leukemia.
Kasimir-Bauer S; Beelen D; Flasshove M; Noppeney R; Seeber S; Scheulen ME
Exp Hematol; 2002 Nov; 30(11):1302-8. PubMed ID: 12423683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
